The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.
Patients who receive a heart valve replacement are well-known to be at a high risk for stroke, blood clots and deep vein thrombosis, especially during the weeks immediately after surgery. Current ...
The CLEAR SYNERGY trial found that spironolactone may reduce the risk of new or worsening heart failure; however, it did not significantly impact the rate of death, new heart attack or stroke.